The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis

European Heart Journal

Volumn 36, Issue 42, 2015, Pages 2909-2919

  Corsten, Maarten ^a   Heggermont, Ward ^a,b,c   Papageorgiou, Anna Pia ^a,b   Deckx, Sophie ^a   Tijsma, Aloys ^d   Verhesen, Wouter ^a   Van Leeuwen, Rick ^a   Carai, Paolo ^a,b   Thibaut, Hendrik Jan ^d   Custers, Kevin ^a   Summer, Georg ^a   Hazebroek, Mark ^a   Verheyen, Fons ^e   Neyts, Johan ^d   Schroen, Blanche ^a   Heymans, Stephane ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adverse inflammation; Coxsackievirus B3; Dilated cardiomyopathy; Myocarditis; Viral replication

Indexed keywords

BCL 2 MODIFYING FACTOR; BCL2 LIKE 11; BETA INTERFERON; GAMMA INTERFERON; HIGH MOBILITY GROUP B PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA 221; MICRORNA 222; PROTEIN BCL 2; STROMAL CELL DERIVED FACTOR 1; THYMOCYTE SELECTION ASSOCIATED HIGH MOBILITY GROUP BOX PROTEIN; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MICRORNA; MIRN221 MICRORNA, MOUSE; MIRN222 MICRORNA, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; COXSACKIEVIRUS B3; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HEART INJURY; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; UPREGULATION; VIRUS LOAD; VIRUS MYOCARDITIS; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C3H MOUSE; C57BL MOUSE; CARDIAC MUSCLE CELL; CELLULAR IMMUNITY; IMMUNOLOGY; MACROPHAGE; MALE; METABOLISM; MYOCARDITIS; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY;

ANIMALS; COXSACKIEVIRUS INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MACROPHAGES; MALE; MICE, INBRED C3H; MICE, INBRED C57BL; MICRORNAS; MYOCARDITIS; MYOCYTES, CARDIAC; T-LYMPHOCYTES; UP-REGULATION; VIRAL LOAD; VIRUS REPLICATION;

EID: 84948652735     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv321     Document Type: Article

References (40)

1. Cooper LT Jr. Myocarditis. N Engl J Med 2009;360:1526-1538.
2. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010;52:274-288.
3. Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Ann Rev Pathol 2008;3:127-155.
4. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-275.
5. Corsten MF, Schroen B, Heymans S. Inflammation in viral myocarditis: friend or foe? Trends Mol Med 2012;18:426-437.
6. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136: 215-233.
7. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011;469:336-342.
8. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111-122.
9. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010;107:264-269.
10. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, Stein GS. Micro-RNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008;68:2773-2780.
11. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res 2012; 110:508-522.
12. Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009;104:476-487.
13. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, Hammond S, Rainaldi G. MicroRNAs modulate the angiogenic properties of HU-VECs. Blood 2006;108:3068-3071.
14. Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, Summer G, Coort SL, Hazebroek M, van Leeuwen R, Gijbels MJ, Wijnands E, Biessen EA, De Winther MP, Stassen FR, Carmeliet P, Kauppinen S, Schroen B, Heymans S. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res 2012;111:415-425.
15. Huber SA, Gauntt CJ, Sakkinen P. Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv Virus Res 1998;51:35-80.
16. Huber SA. Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d. Med Microbiol Immunol 2005;194: 121-127.
17. Huber SA. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab Invest 1997;76:691-701.
18. Suarez Y, Wang C, Manes TD, Pober JS. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol 2010;184:21-25.
19. Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional MicroRNAs in macrophages with polarized phenotypes. J Biol Chem 2012;287: 21816-21825.
20. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 2005;115:2508-2516.
21. Russell L, Garrett-Sinha LA. Transcription factor Ets-1 in cytokine and chemokine gene regulation. Cytokine 2010;51:217-226.
22. Cheng C, Tempel D, Den Dekker WK, Haasdijk R, Chrifi I, Bos FL, Wagtmans K, van de Kamp EH, Blonden L, Biessen EA, Moll F, Pasterkamp G, Serruys PW, Schulte-Merker S, Duckers HJ. Ets2 determines the inflammatory state of endothelial cells in advanced atherosclerotic lesions. Circ Res 2011;109:382-395.
23. Sieweke MH, Tekotte H, Jarosch U, Graf T. Cooperative interaction of ets-1 with USF-1 required for HIV-1 enhancer activity in T cells. EMBO J 1998;17:1728-1739.
24. Posada R, Pettoello-Mantovani M, Sieweke M, Graf T, Goldstein H. Suppression of HIV type 1 replication by a dominant-negative Ets-1 mutant. AIDS Res Hum Retroviruses 2000;16:1981-1989.
25. Bosselut R, Duvall JF, Gegonne A, Bailly M, Hemar A, Brady J, Ghysdael J. The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1. EMBO J 1990;9:3137-3144.
26. Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793-2798.
27. Welsh RM. Regulation of virus infections by natural killer cells. A review. Nat Immun Cell Growth Regul 1986;5:169-199.
28. Johansson SE, Brauner H, Hinkula J, Wahren B, Berg L, Johansson MH. Accumulation and activation of natural killer cells in local intraperitoneal HIV-1/MuLV infection results in early control of virus infected cells. Cell Immunol 2011;272: 71-78.
29. Lindner D, Hilbrandt M, Marggraf K, Becher PM, Hilfiker-Kleiner D, Klingel K, Pauschinger M, Schultheiss HP, Tschope C, Westermann D. Protective function of STAT3 in CVB3-induced myocarditis. Cardiol Res Pract 2012;2012:437623.
30. Camporeale A, Marino F, Papageorgiou A, Carai P, Fornero S, Fletcher S, Page BD, Gunning P, Forni M, Chiarle R, Morello M, Jensen O, Levi R, Heymans S, Poli V. STAT3 activity is necessary and sufficient for the development of immunemediated myocarditis in mice and promotes progression to dilated cardiomyopathy. EMBO Mol Med 2013;5:572-590.
31. Ruppert V, Meyer T, Pankuweit S, Jonsdottir T, Maisch B. Activation of STAT1 transcription factor precedes up-regulation of coxsackievirus-adenovirus receptor during viral myocarditis. Cardiovasc Pathol 2008;17:81-92.
32. Sherry B. The role of interferon regulatory factors in the cardiac response to viral infection. Viral Immunol 2002;15:17-28.
33. Dai R, Li J, Liu Y, Yan D, Chen S, Duan C, Liu X, He T, Li H. miR-221/222 suppression protects against endoplasmic reticulum stress-induced apoptosis via p27(Kip1)- and MEK/ERK-mediated cell cycle regulation. Biol Chem 2010;391:791-801.
34. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu WT. Altered microRNA expression in human heart disease. Physiol Genomics 2007;31: 367-373.
35. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008;45:185-192.
36. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100:416-424.
37. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007;42:1137-1141.
38. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, Gnyawali S, Shilo S, Nuovo GJ, Sen CK. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009;82:21-29.
39. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008;105: 13027-13032.
40. Luk A, Ahn E, Soor GS, Butany J. Dilated cardiomyopathy: a review. J Clin Pathol 2009;62:219-225.